[1]
|
Morgan, L.L. (2015) The Epidemiology of Glioma in Adults: A “State of the Science” Review. Neuro-Oncology, 17, 623-624. https://doi.org/10.1093/neuonc/nou358
|
[2]
|
Ostrom, Q.T., Gittleman, H., Liao, P., et al. (2014) CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011. Neuro-Oncology, 16, iv1-iv63.
https://doi.org/10.1093/neuonc/nou223
|
[3]
|
Jiang, T., Nam, D.H., Ram, Z., et al. (2021) Clinical Practice Guidelines for the Management of Adult Diffuse Gliomas. Cancer Letters, 499, 60-72. https://doi.org/10.1016/j.canlet.2020.10.050
|
[4]
|
Osswald, M., Jung, E., Sahm, F., et al. (2015) Brain Tumour Cells Interconnect to a Functional and Resistant Network. Nature, 528, 93-98. https://doi.org/10.1038/nature16071
|
[5]
|
Stupp, R., Hegi, M.E., Mason, W.P., et al. (2009) Effects of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase III Study: 5-Year Analysis of the EORTC-NCIC Trial. The Lancet Oncology, 10, 459-466. https://doi.org/10.1016/S1470-2045(09)70025-7
|
[6]
|
Brandes, A.A., Tosoni, A., Franceschi, E., Reni, M., Gatta, G. and Vecht, C. (2008) Glioblastoma in Adults. Critical Reviews in Oncology/Hematology, 67, 139-152. https://doi.org/10.1016/j.critrevonc.2008.02.005
|
[7]
|
Sandmann, T., Bourgon, R., Garcia, J., et al. (2015) Patients with Proneural Glioblastoma May Derive Overall Survival Benefit from the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. Journal of Clinical Oncology, 33, 2735-2744. https://doi.org/10.1200/JCO.2015.61.5005
|
[8]
|
Pasqualetti, F., Gonnelli, A., Molinari, A., et al. (2018) Different Timing to Use Bevacizumab in Patients with Recurrent Glioblastoma: Early versus Delayed Administration. Anticancer Research, 38, 5877-5881.
https://doi.org/10.21873/anticanres.12930
|
[9]
|
Chinot, O.L., Wick, W., Mason, W., et al. (2014) Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma. The New England Journal of Medicine, 370, 709-722. https://doi.org/10.1056/NEJMoa1308345
|
[10]
|
Chaudhry, A., Benson, L., Varshaver, M., et al. (2015) NovoTTF™-100A System (Tumor Treating Fields) Transducer Array Layout Planning for Glioblastoma: A NovoTAL™ System User Study. World Journal of Surgical Oncology, 13, Article No. 316. https://doi.org/10.1186/s12957-015-0722-3
|
[11]
|
Stupp, R., Taillibert, S., Kanner, A., et al. (2017) Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. Journal of the American Medical Association, 318, 2306-2316. https://doi.org/10.1001/jama.2017.18718
|
[12]
|
Rominiyi, O., Vanderlinden, A., Clenton, S.J., Bridgewater, C., Al-Tamimi, Y. and Collis, S.J. (2021) Tumour Treating Fields Therapy for Glioblastoma: Current Advances and Future Directions. British Journal of Cancer, 124, 697-709. https://doi.org/10.1038/s41416-020-01136-5
|
[13]
|
Murciano-Goroff, Y.R., Warner, A.B. and Wolchok, J.D. (2020) The Future of Cancer Immunotherapy: Microenvironment-Targeting Combinations. Cell Research, 30, 507-519. https://doi.org/10.1038/s41422-020-0337-2
|
[14]
|
Gerstner, E.R. and Fine, R.L. (2007) Increased Permeability of the Blood-Brain Barrier to Chemotherapy in Metastatic Brain Tumors: Establishing a Treatment Paradigm. Journal of Clinical Oncology, 25, 2306-2312.
https://doi.org/10.1200/JCO.2006.10.0677
|
[15]
|
Bagchi, S., Chhibber, T., Lahooti, B., Verma, A., Borse, V. and Jayant, R.D. (2019) In-Vitro Blood-Brain Barrier Models for Drug Screening and Permeation Studies: An Overview. Drug Design, Development and Therapy, 13, 3591-3605.
https://doi.org/10.2147/DDDT.S218708
|
[16]
|
Chowdhury, E.A., Noorani, B., Alqahtani, F., et al. Understanding the Brain Uptake and Permeability of Small Molecules through the BBB: A Technical Overview. Journal of Cerebral Blood Flow & Metabolism, 41, 1797-1820.
https://doi.org/10.1177/0271678X20985946
|
[17]
|
Verhaak, R.G., Hoadley, K.A., Purdom, E., et al. (2010) Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 17, 98-110. https://doi.org/10.1016/j.ccr.2009.12.020
|
[18]
|
Neftel, C., Laffy, J., Filbin, M.G., et al. (2019) An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell, 178, 835-849.E21. https://doi.org/10.1016/j.cell.2019.06.024
|
[19]
|
Helleday, T., Petermann, E., Lundin, C., Hodgson, B. and Sharma, R.A. (2008) DNA Repair Pathways as Targets for Cancer Therapy. Nature Reviews Cancer, 8, 193-204. https://doi.org/10.1038/nrc2342
|
[20]
|
Huang, Z., Cheng, L., Guryanova, O.A., Wu, Q. and Bao, S. (2010) Cancer Stem Cells in Glioblastoma-Molecular Signaling and Therapeutic Targeting. Protein & Cell, 1, 638-655. https://doi.org/10.1007/s13238-010-0078-y
|
[21]
|
Morgan, M.A. and Canman, C.E. (2018) Replication Stress: An Achilles’ Heel of Glioma Cancer Stem-Like Cells. Cancer Research, 78, 6713-6716. https://doi.org/10.1158/0008-5472.CAN-18-2439
|
[22]
|
Aldape, K., Brindle, K.M., Chesler, L., et al. (2019) Challenges to Curing Primary Brain Tumours. Nature Reviews Clinical Oncology, 16, 509-520. https://doi.org/10.1038/s41571-019-0177-5
|
[23]
|
Ngoi, N.Y.L., Pham, M.M., Tan, D.S.P. and Yap, T.A. (2021) Targeting the Replication Stress Response through Synthetic Lethal Strategies in Cancer Medicine. Trends in Cancer, 7, 930-957. https://doi.org/10.1016/j.trecan.2021.06.002
|
[24]
|
Zeman, M.K. and Cimprich, K.A. (2014) Causes and Consequences of Replication Stress. Nature Cell Biology, 16, 2-9. https://doi.org/10.1038/ncb2897
|
[25]
|
Harper, J.W. and Elledge, S.J. (2007) The DNA Damage Response: Ten Years after. Molecular Cell, 28, 739-745.
https://doi.org/10.1016/j.molcel.2007.11.015
|
[26]
|
Blackford, A.N. and Jackson, S.P. (2017) ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response. Molecular Cell, 66, 801-817. https://doi.org/10.1016/j.molcel.2017.05.015
|
[27]
|
Jackson, S.P. and Bartek, J. (2009) The DNA-Damage Response in Human Biology and Disease. Nature, 461, 1071- 1078. https://doi.org/10.1038/nature08467
|
[28]
|
Toledo, L., Neelsen, K.J. and Lukas, J. (2017) Replication Catastrophe: When a Checkpoint Fails Because of Exhaustion. Molecular Cell, 66, 735-749. https://doi.org/10.1016/j.molcel.2017.05.001
|
[29]
|
Damia, G. (2020) Targeting DNA-PK in Cancer. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 821, Article ID: 111692. https://doi.org/10.1016/j.mrfmmm.2020.111692
|
[30]
|
Stagni, V., Oropallo, V., Fianco, G., Antonelli, M., Cinà, I. and Barilà, D. (2014) Tug of War between Survival and Death: Exploring ATM Function in Cancer. International Journal of Molecular Sciences, 15, 5388-5409.
https://doi.org/10.3390/ijms15045388
|
[31]
|
Armstrong, S.A., Schultz, C.W., Azimi-Sadjadi, A., Brody, J.R. and Pishvaian, M.J. (2019) ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications. Molecular Cancer Therapeutics, 18, 1899-1908.
https://doi.org/10.1158/1535-7163.MCT-19-0208
|
[32]
|
Curtin, N.J. (2012) DNA Repair Dysregulation from Cancer Driver to Therapeutic Target. Nature Reviews Cancer, 12, 801-817. https://doi.org/10.1038/nrc3399
|
[33]
|
Maréchal, A. and Zou, L. (2013) DNA Damage Sensing by the ATM and ATR Kinases. Cold Spring Harbor Perspectives in Biology, 5, a012716. https://doi.org/10.1101/cshperspect.a012716
|
[34]
|
Shiloh, Y. and Ziv, Y. (2013) The ATM Protein Kinase: Regulating the Cellular Response to Genotoxic Stress, and More. Nature Reviews Molecular Cell Biology, 14, 197-210. https://doi.org/10.1038/nrm3546
|
[35]
|
Ferri, A., Stagni, V. and Barilà, D. (2020) Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma. International Journal of Molecular Sciences, 21, Article No. 4910.
https://doi.org/10.3390/ijms21144910
|
[36]
|
Bakr, A., Oing, C., Köcher, S., et al. (2015) Involvement of ATM in Homologous Recombination after End Resection and RAD51 Nucleofilament Formation. Nucleic Acids Research, 43, 3154-3166. https://doi.org/10.1093/nar/gkv160
|
[37]
|
Ciccia, A. and Elledge, S.J. (2010) The DNA Damage Response: Making It Safe to Play with Knives. Molecular Cell, 40, 179-204. https://doi.org/10.1016/j.molcel.2010.09.019
|
[38]
|
Mailand, N., Falck, J., Lukas, C., et al. (2000) Rapid Destruction of Human Cdc25A in Response to DNA Damage. Science, 288, 1425-1429. https://doi.org/10.1126/science.288.5470.1425
|
[39]
|
Toledo, L.I., Altmeyer, M., Rask, M.B., et al. (2013) ATR Prohibits Replication Catastrophe by Preventing Global Exhaustion of RPA. Cell, 155, 1088-1103. https://doi.org/10.1016/j.cell.2013.10.043
|
[40]
|
Damia, G. (2020) Targeting DNA-PK in Cancer. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 821, Article ID: 111692. https://doi.org/10.1016/j.mrfmmm.2020.111692
|
[41]
|
Zhang, Y.W., Jones, T.L., Martin, S.E., Caplen, N.J. and Pommier, Y. (2009) Implication of Checkpoint Kinase- Dependent Up-Regulation of Ribonucleotide Reductase R2 in DNA Damage Response. Journal of Biological Chemistry, 284, 18085-18095. https://doi.org/10.1074/jbc.M109.003020
|
[42]
|
Li, X. and Heyer, W.D. (2008) Homologous Recombination in DNA Repair and DNA Damage Tolerance. Cell Research, 18, 99-113. https://doi.org/10.1038/cr.2008.1
|
[43]
|
Chang, H.H.Y., Pannunzio, N.R., Adachi, N. and Lieber, M.R. (2017) Non-Homologous DNA End Joining and Alternative Pathways to Double-Strand Break Repair. Nature Reviews Molecular Cell Biology, 18, 495-506.
https://doi.org/10.1038/nrm.2017.48
|
[44]
|
Degan, P., Cappelli, E., Regis, S. and Ravera, S. (2019) New Insights and Perspectives in Fanconi Anemia Research. Trends in Molecular Medicine, 25, 167-170. https://doi.org/10.1016/j.molmed.2019.01.003
|
[45]
|
Denny, B.J., Wheelhouse, R.T., Stevens, M.F., Tsang, L.L. and Slack, J.A. (1994) NMR and Molecular Modeling Investigation of the Mechanism of Activation of the Antitumor Drug Temozolomide and Its Interaction with DNA. Biochemistry, 33, 9045-9051. https://doi.org/10.1021/bi00197a003
|
[46]
|
Tisdale, M.J. (1987) Antitumor Imidazotetrazines—XV. Role of Guanine O6 Alkylation in the Mechanism of Cytotoxicity of Imidazotetrazinones. Biochemical Pharmacology, 36, 457-462.
https://doi.org/10.1016/0006-2952(87)90351-0
|
[47]
|
Mojas, N., Lopes, M. and Jiricny, J. (2007) Mismatch Repair-Dependent Processing of Methylation Damage Gives Rise to Persistent Single-Stranded Gaps in Newly Replicated DNA. Genes & Development, 21, 3342-3355.
https://doi.org/10.1101/gad.455407
|
[48]
|
Eich, M., Roos, W.P., Nikolova, T. and Kaina, B. (2013) Contribution of ATM and ATR to the Resistance of Glioblastoma and Malignant Melanoma Cells to the Methylating Anticancer Drug Temozolomide. Molecular Cancer Therapeutics, 12, 2529-2540. https://doi.org/10.1158/1535-7163.MCT-13-0136
|
[49]
|
Matt, S. and Hofmann, T.G. (2016) The DNA Damage-Induced Cell Death Response: A Roadmap to Kill Cancer Cells. Cellular and Molecular Life Sciences, 73, 2829-2850. https://doi.org/10.1007/s00018-016-2130-4
|
[50]
|
Fròsina, G., Profumo, A., Marubbi, D., Marcello, D., Ravetti, J.L. and Daga, A. (2018) ATR Kinase Inhibitors NVP- BEZ235 and AZD6738 Effectively Penetrate the Brain after Systemic Administration. Radiation Oncology, 13, Article No. 76. https://doi.org/10.1186/s13014-018-1020-3
|
[51]
|
Carruthers, R.D., Ahmed, S.U., Ramachandran, S., et al. (2018) Replication Stress Drives Constitutive Activation of the DNA Damage Response and Radioresistance in Glioblastoma Stem-Like Cells. Cancer Research, 78, 5060-5071.
https://doi.org/10.1158/0008-5472.CAN-18-0569
|
[52]
|
Biddlestone-Thorpe, L., Sajjad, M., Rosenberg, E., et al. (2013) ATM Kinase Inhibition Preferentially Sensitizes p53- Mutant Glioma to Ionizing Radiation. Clinical Cancer Research, 19, 3189-3200.
https://doi.org/10.1158/1078-0432.CCR-12-3408
|
[53]
|
Durant, S.T., Zheng, L., Wang, Y., et al. (2018) The Brain-Penetrant Clinical ATM Inhibitor AZD1390 Radiosensitizes and Improves Survival of Preclinical Brain Tumor Models. Science Advances, 4, eaat1719.
https://doi.org/10.1126/sciadv.aat1719
|
[54]
|
Jucaite, A., Stenkrona, P., Cselényi, Z., et al. (2021) Brain Exposure of the ATM Inhibitor AZD1390 in Humans—A Positron Emission Tomography Study. Neuro-Oncology, 23, 687-696. https://doi.org/10.1093/neuonc/noaa238
|
[55]
|
Bao, S., Wu, Q., McLendon, R.E., et al. (2006) Glioma Stem Cells Promote Radioresistance by Preferential Activation of the DNA Damage Response. Nature, 444, 756-760. https://doi.org/10.1038/nature05236
|
[56]
|
Patties, I., Kallendrusch, S., Böhme, L., et al. (2019) The Chk1 Inhibitor SAR-020106 Sensitizes Human Glioblastoma Cells to Irradiation, to Temozolomide, and to Decitabine Treatment. Journal of Experimental & Clinical Cancer Research, 38, Article No. 420. https://doi.org/10.1186/s13046-019-1434-2
|
[57]
|
Alexander, B., Supko, J., Agar, N., Ahluwalia, M., Desai, A., Dietrich, J., Kaley, T., Peereboom, D., Takebe, N., Desideri, S., et al. (2018) ACTR-14. Phase I Study of AZD1775 with Radiation Therapy (RT) and Temozolomide (TMZ) in Patients with Newly Diagnosed Glioblastoma (GBM) and Evaluation of Intratumoral Drug Distribution in Patients with Recurrent GBM. Neuro-Oncology, 20, vi13-vi14. https://doi.org/10.1093/neuonc/noy148.048
|
[58]
|
Wick, W., Weller, M., van den Bent, M., et al. (2014) MGMT Testing—The Challenges for Biomarker-Based Glioma Treatment. Nature Reviews Neurology, 10, 372-385. https://doi.org/10.1038/nrneurol.2014.100
|
[59]
|
Wood, R.D., Mitchell, M., Sgouros, J. and Lindahl, T. (2001) Human DNA Repair Genes. Science, 291, 1284-1289.
https://doi.org/10.1126/science.1056154
|
[60]
|
Hegi, M.E., Diserens, A.C., Gorlia, T., et al. (2005) MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. The New England Journal of Medicine, 352, 997-1003. https://doi.org/10.1056/NEJMoa043331
|
[61]
|
Mellai, M., Monzeglio, O., Piazzi, A., et al. (2012) MGMT Promoter Hypermethylation and Its Associations with Genetic Alterations in a Series of 350 Brain Tumors. Journal of Neuro-Oncology, 107, 617-631.
https://doi.org/10.1007/s11060-011-0787-y
|
[62]
|
Fan, C.H., Liu, W.L., Cao, H., Wen, C., Chen, L. and Jiang, G. (2013) O6-Methylguanine DNA Methyltransferase as a Promising Target for the Treatment of Temozolomide-Resistant Gliomas. Cell Death & Disease, 4, e876.
https://doi.org/10.1038/cddis.2013.388
|
[63]
|
Jackson, C.B., Noorbakhsh, S.I., Sundaram, R.K., et al. (2019) Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors. Cancer Research, 79, 4331-4338. https://doi.org/10.1158/0008-5472.CAN-18-3394
|
[64]
|
Middleton, M.R. and Margison, G.P. (2003) Improvement of Chemotherapy Efficacy by Inactivation of a DNA-Repair Pathway. The Lancet Oncology, 4, 37-44. https://doi.org/10.1016/S1470-2045(03)00959-8
|
[65]
|
Quinn, J.A., Jiang, S.X., Reardon, D.A., et al. (2009) Phase II Trial of Temozolomide plus O6-Benzylguanine in Adults with Recurrent, Temozolomide-Resistant Malignant Glioma. Journal of Clinical Oncology, 27, 1262-1267.
https://doi.org/10.1200/JCO.2008.18.8417
|
[66]
|
Hickson, I.D. (1997) Base Excision Repair of DNA Damage. Landes Bioscience and Chapman & Hall, Austin.
|
[67]
|
Wu, S., Li, X., Gao, F., de Groot, J.F., Koul, D. and Yung, W.K.A. (2021) PARP-Mediated PARylation of MGMT Is Critical to Promote Repair of Temozolomide-Induced O6-Methylguanine DNA Damage in Glioblastoma. Neuro-Oncology, 23, 920-931. https://doi.org/10.1093/neuonc/noab003
|
[68]
|
Higuchi, F., Nagashima, H., Ning, J., Koerner, M.V.A., Wakimoto, H. and Cahill, D.P. (2020) Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma Is Independent of Base Excision Repair. Clinical Cancer Research, 26, 1690-1699. https://doi.org/10.1158/1078-0432.CCR-19-2000
|
[69]
|
Farmer, H., McCabe, N., Lord, C.J., et al. (2005) Targeting the DNA Repair Defect in BRCA Mutant Cells as a Therapeutic Strategy. Nature, 434, 917-921. https://doi.org/10.1038/nature03445
|
[70]
|
Bryant, H.E., Schultz, N., Thomas, H.D., et al. (2005) Specific Killing of BRCA2-Deficient Tumours with Inhibitors of Poly(ADP-Ribose) Polymerase. Nature, 434, 913-917. https://doi.org/10.1038/nature03443
|
[71]
|
Mateo, J., Lord, C.J., Serra, V., et al. (2019) A Decade of Clinical Development of PARP Inhibitors in Perspective. Annals of Oncology, 30, 1437-1447. https://doi.org/10.1093/annonc/mdz192
|
[72]
|
Ning, J. and Wakimoto, H. (2020) Therapeutic Application of PARP Inhibitors in Neuro-Oncology. Trends in Cancer, 6, 147-159. https://doi.org/10.1016/j.trecan.2019.12.004
|
[73]
|
Sulkowski, P.L., Oeck, S., Dow, J., et al. (2020) Oncometabolites Suppress DNA Repair by Disrupting Local Chromatin Signalling. Nature, 582, 586-591. https://doi.org/10.1038/s41586-020-2363-0
|
[74]
|
Wang, Y., Wild, A.T., Turcan, S., et al. (2020) Targeting Therapeutic Vulnerabilities with PARP Inhibition and Radiation in IDH-Mutant Gliomas and Cholangiocarcinomas. Science Advances, 6, eaaz3221.
https://doi.org/10.1126/sciadv.aaz3221
|
[75]
|
Sim, H.W., McDonald, K.L., Lwin, Z., et al. (2021) A Randomized Phase II Trial of Veliparib, Radiotherapy, and Temozolomide in Patients with Unmethylated MGMT Glioblastoma: The VERTU Study. Neuro-Oncology, 23, 1736- 1749. https://doi.org/10.1093/neuonc/noab111
|